Inhibrx Biosciences, Inc. · NASDAQ:INBX

Inhibrx Biosciences — Investor Presentation (August 2026)

28 slides from Inhibrx Biosciences's investor presentation, August 2026

  1. Slide 1: Investor Presentation

    INHIBRX Investor Presentation Innovation Driven Outcomes Focused •

  2. Slide 2: Presentation disclaimer

    Presentation disclaimer This presentation of Inhibrx Biosciences, Inc. (the “Company”) contains forward-looking 10-Q, and supplemented from time to time by our Current Reports on Form 8-K. statements. In some cases, you can identify forward-looking statements by the words “will,” The Company may not

  3. Slide 3: Our mission: To discover & develop effective biologic treatments

    Our mission: To discover & develop effective biologic treatments for people with life-threatening conditions Key financial highlights >300 ozekibart (INBRX-109) (as of 8/6/2026) Patients treated to date $219.5M Biosciences >175 Cash and cash INBRX-106 equivalents Patients treated 2024 to date 14.7M

  4. Slide 4: Near term expected milestones

    Near term expected milestones INBRX-106 Initiation of Phase 3 portion Ozekibart INBRX-106 of HexAgon (INBRX-109) Data for randomized, Potential approval and first line HNSCC (INBRX- first commercial launch 106/ Pembro vs. of ozekibart for the Pembro) treatment of metastatic or unresectable chondrosa

  5. Slide 5: INBRX-106

    INBRX-106 Boosting PD-1 efficacy through next-generation hexavalent OX40 agonism

  6. Slide 6: OX40 agonism enhances anti-tumor T cell activity in combo with PD-1 blockade

    OX40 agonism enhances anti-tumor T cell activity in combo with INBRX-106 PD-1 blockade Optimized T cell activation by T-cell activation critical steps: OX40 agonism and PD-1 blockade The ignition The accelerator The brake Signal 1: TCR tumor Signal 2: OX40 T-cell Check point antigen recognition co-s

  7. Slide 7: INBRX-106 is a hexavalent agonist designed to maximize OX40 signaling

    INBRX-106 is a hexavalent agonist designed to maximize OX40 INBRX-106 signaling to drive antitumor activity Hexavalent OX40 Agonist High-order OX40 clustering leads to stronger signal potency 2500 JITC Providence Publication High-order 2000 OX40 clustering Mean Value 1500 OX40 by INBRX-106 1000 500

  8. Slide 8: Seamless Phase 2/3 study in 1L R/M HNSCC with PD-L1 CPS ≥20

    INBRX-106 Seamless Phase 2/3 study in 1L R/M HNSCC with PD-L1 CPS ≥20 INBRX-106 with pembrolizumab: costimulatory proof of concept study Phase 2, Phase 3, Survival Open label Double blind Follow-up Randomization will be stratified by: • Disease status Primary Co-primary INBRX-106 Criteria: INBRX-106

  9. Slide 9: Interim HexAgon Phase 2 data in 1L HNSCC

    Interim HexAgon Phase 2 data in 1L HNSCC demonstrate INBRX-106 INBRX-106 Potential costimulatory benefit over PD-1 monotherapy Improvement in cORR with Pharmacodynamic evidence of Manageable safety profile consistent superior depth of response potent T-Cell co-activation with immunotherapy combinati

  10. Slide 10: Interim phase 2 data in HNSCC: INBRX-106 + Pembro vs. Pembro

    Interim phase 2 data in HNSCC: INBRX-106 + Pembro vs. Pembro INBRX-106 Best Overall Response INBRX-106 + Pembrolizumab Pembrolizumab 100 Best Overall Response 100 Best Overall Response PD PD 80 80 SD SD PR PR 60 60 CR CR 40 40 *Patients ongoing on study without PD event Change from Baseline, % Chang

  11. Slide 11: INBRX-106 + Pembro drives up to 15-fold change in proliferation

    INBRX-106 + Pembro drives up to 15-fold change in proliferation INBRX-106 and up to 4-fold change in activation of T-cells HexAgon Phase 2 – 1L HNSCC Proliferation Activation 25 5 • INBRX-106 is the key driver Baseline – % of Activated Baseline – % of Activated of T-cell activity in the Max Fold Cha

  12. Slide 12: Broad expandability: development plan to unlock opportunities in NSCLC, H&N and beyond

    Broad expandability: development plan to unlock opportunities INBRX-106 in NSCLC, H&N and beyond 106 + pembro Ph3 1L /M PD-L1 CPS≥20 pembro H&N1 106 pembro + ctx Ph2 PoC 106 Ph3 perioperative neoadjuvant + pembro +ctx neoadj + adjuvant Pembro + ctx Curative 106 + pembro 1L PD-L1 high TPS≥50% pembro

  13. Slide 13: Inhibrx path to oncology market leadership

    INBRX-106 Inhibrx path to oncology market leadership Demonstrate INBRX-106 Contribution Pursue significant market Expand INBRX-106 to wherever of Benefit via Head & Neck value in NSCLC PD-1s are Effective Randomize INBRX-106+pembro vs. pembro Three studies: pembro+106 in 1L TPS > 50% +10-20 addition

  14. Slide 14: Phase 1 data: PD-L1+ CPI-R/R NSCLC

    INBRX-106 Phase 1 data: PD-L1+ CPI-R/R NSCLC INBRX-106 with pembrolizumab 60 40 PD 20 Change from baseline, % Change from Baseline, % 0 -20 PR -40 -60 Treatment Duration (months) -80 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 PD-L1 TPS 60 20 95 10 80 80 90 2 11 20 3 75

  15. Slide 15: Phase 1 data: PD-L1+ CPI-R/R or CPI-naive HNSCC

    INBRX-106 Phase 1 data: PD-L1+ CPI-R/R or CPI-naive HNSCC INBRX-106 with pembrolizumab 60 Cohort COI-naïve (F4) 40 CPI-R/R (F1) NPC* Patient (D2) PD 20 Change from baseline, % Best Change from Baseline, % 0 -20 PR -40 -60 Treatment Duration (months) -80 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 PD-L1

  16. Slide 16: Ozekibart (INBRX-109)

    Ozekibart (INBRX-109) Selectively inducing apoptosis in tumor cells through tetravalent DR5 agonism

  17. Slide 17: Ozekibart chondrosarcoma registrational trial results

    INBRX-109 Ozekibart (INBRX-109) chondrosarcoma registrational trial results Unprecedented data in chondrosarcoma 52% reduction in Median PFS more Improved disease Regulatory progression or death than doubled control rate momentum HR 0.479; 5.52 months vs 54% vs 27.5% Orphan designations (FDA & EMA)

  18. Slide 18: Primary endpoint: progression-free survival by CIRR

    INBRX-109 Primary endpoint: progression-free survival by CIRR Ozekibart Placebo 3 months 6 months 12 months N=137 N=69 1.0 Primary Efficacy Endpoint 70.1% Events 94 (68.6) 55 (79.7) / Censored, n (%) / 43 (31.4) / 14 (20.3) 0.8 mPFS, months 5.52 2.66 47.2% Stratified HR 0.479 Probability of PFS 0.6

  19. Slide 19: Progression-free survival by CIRR: subgroup analyses

    Progression-free survival by CIRR: subgroup analyses INBRX-109 0 favors Ozekibart 1 2 3 Ozekibart Placebo Events, n/Na mPFS, mo Events, n/Na mPFS, mo HR (95% CI) IDH mutation Wild type 65/93 5.5 38/47 2.7 0.493 (0.324-0.750) status Mutant 29/44 5.5 17/22 2.3 0.442 (0.224-0.871) Prior Yes 38/58 5.3 2

  20. Slide 20: Overall safety data

    INBRX-109 Overall safety data Double-blind period Ozekibart Placebo N=136 N=67 Patients with ≥1 AE (including unrelated AEs), n (%) 129 (94.9) 62 (92.5) Grade ≥3 53 (39.0) 17 (25.4) SAE 38 (27.9) 12 (17.9) HAE 21 (15.4) 9 (13.4) Resulting in death 5 (3.7) 1 (1.5) Patients with ≥1 treatment-related A

  21. Slide 21: Initial data from Phase 1/2 colorectal adenocarcinoma with FOLFIRI

    Initial data from Phase 1/2 colorectal adenocarcinoma in INBRX-109 combination with FOLFIRI Key inclusion criteria CRC 3-4L with FOLFIRI 45 patients evaluable for response • LA/M, unresectable, R/R N=50 ~70% are 4th line & ~30% are 3rd line colorectal adenocarcinoma ~80% have received prior IRI-cont

  22. Slide 22: Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI

    INBRX-109 Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI CR PR SD PR SD PR SD SD SD SD PR SD Individual patient time on treatment shows sustained SD SD disease control in heavily SD SD PR SD pre-treated patients SD SD SD SD PR SD Prior Treatment Status: PR SD 2 lines of prior therap

  23. Slide 23: Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI

    Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI INBRX-109 40 32 Benchmarks ORR (%) 26 25 22 PDa Lonsurf + bev 20 17 (SUNLIGHT, 2023) 6.1 11 regorafenib 5 5 (CORRECT, 2013) 1.0 0 fruquintinib -3 -3 -3 -3 -4 (FRESCO-2, 2023) 1.5 Change from Baseline, % -6 -7 -10 -11 -14 -15 -20 -16 -16

  24. Slide 24: CRC expansion cohorts: open and enrolling

    CRC expansion cohorts: open and enrolling COMBINATION (n=270) Part 3: dose expansion Colorectal adenocarcinoma (LA/M, unresectable, R/R) Ozekibart + chemotherapy ONGOING • Patients with no prior exposure to IRI-based regimen C4e • 1 prior line of systemic therapy CURRENTLY ENROLLING (n≈30) Regimen:

  25. Slide 25: Ongoing phase 1/2 trial in Ewing sarcoma in combination with IRI/TMZ

    Ongoing phase 1/2 trial in Ewing sarcoma in combination INBRX-109 with IRI/TMZ Key inclusion criteria EWS 2-3L with IRI/TMZ • LA/M, unresectable, R/R EWS N=50 • Aged ≥12 to <85 years • EWSR1-FLI1, -ERG or -FEV rearrangement Ozekibart 3 mg/kg + IRI • 1-2 prior lines of chemotherapy in metastatic sett

  26. Slide 26: Updated data from expansion cohort: Ewing sarcoma

    Updated data from expansion cohort: Ewing sarcoma in INBRX-109 combination with IRI/TMZ 100 Prior IRI/TMZ Treatment Recruitment ongoing 80 Yes 39 patients dosed with 31 patients currently evaluable for response: 60 40 (N=31) Change from Baseline, % PD 20 87.1% 0 Disease control rate was 87.1%, or 27

  27. Slide 27: Ozekibart exhibits anti-tumor activity in GBM models

    Ozekibart exhibits anti-tumor activity in GBM models INBRX-109 as monotherapy and in combination with TMZ Human GBM cell line models In vitro cytotoxicity In vitro cytotoxicity Intracranial U-87 MG Intracranial U-87 MG U-87 MG GBM cell lines Survival analysis Survival analysis • Combination treatmen

  28. Slide 28: Investor Relations

    Investor Relations: KELLY DECK, CPA CFO 11025 N. Torrey Pines Road Suite 140 La Jolla, CA 92037 858.795.4260 [email protected]

Inhibrx Biosciences — Investor Presentation (August 2026) on 6ix